Agoracom Blog Home

Author Archive

« Older Entries
Newer Entries »

Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

Posted by AGORACOM-JC at 12:18 PM on Wednesday, June 23rd, 2021
  • Strategic focus on developing and delivering psychedelic medicines to treat Addiction.
  • Strong psychedelic drug development pipeline targeting Addiction.
  • First mover advantage for clinics in the UK and the EU with 400m people and CAD$25TR GDP.
  • The leading research and clinical team in the industry focused on using psychedelics to treat Addiction.
  • Multiple scalable revenue streams across drug development and clinical delivery.

Toronto, Ontario–(June 23, 2021) – Awakn Life Sciences Corp. (NEO: AWKN) (“Awakn” or the “Company“) a biotechnology company with clinical operations developing, and delivering psychedelic medicines to treat Addiction, is pleased to announce it will begin trading today, June 23, 2021, on the NEO Exchange Inc. (the “NEO”) under the symbol “AWKN”.

“Listing on the NEO is an important milestone for Awakn to continue to build on our dual strategic focus of developing psychedelic drugs, therapies, and enabling technologies to treat Addiction, and delivering psychedelic treatments for Addiction in our clinics,” said Awakn CEO, Anthony Tennyson. “The NEO listing will enable us to accelerate the execution of our drug discovery, therapy development, advanced analytics, and open clinic roll out programs.”

The listing follows the successful completion of the previously announced reverse takeover of a Canadian public company, 2835517 Ontario Ltd., by Toronto-based Awakn Life Sciences Inc. The public company was subsequently renamed Awakn Life Sciences Corp. in connection with the reverse takeover and the listing on the NEO. Additionally, the Company raised gross proceeds of approximately USD$8.3 million through a brokered private placement.

Awakn engaged Canaccord Genuity Corp. and Eight Capital as co-lead agent and joint bookrunners to complete the brokered financing. In connection with the transaction, 2835517 Ontario Ltd. was de-listed from the NEX board of the TSX Venture Exchange.

A filing statement with information about Awakn prepared in accordance with the policies of the NEO is available on SEDAR at www.sedar.com.

About Awakn Life Sciences

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering psychedelic medicine to better treat Addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Forward Looking Statements

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as “forward-looking statements”). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company’s future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “continues”, “forecasts”, “projects”, “predicts”, “intends”, “anticipates”, “targets” or “believes”, or variations of, or the negatives of, such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “should”, “might” or “will” be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company’s public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company’s and Awakn’s securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
[email protected]

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
[email protected]

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
[email protected]

Tags: , , , , , , , , ,
Posted in Awakn Life Sciences Corp., Featured | Comments Off on Awakn Life Sciences to Commence Trading on the NEO Exchange Under the Symbol $AWKN

VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

Posted by AGORACOM-JC at 12:14 PM on Wednesday, June 23rd, 2021

To understand Awakn you first have to understand that …. Psychedelics are going to go through a parabolic, paradigm shifting growth in the next 5 years because of their ability to treat anxiety, depression and addiction … amongst other things Awakn Life Sciences is a biotechnology company with clinical operations developing, and delivering psychedelic medicine to better treat Addiction.  

Awakn has a dual strategic focus: 

  1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
  2. Delivery: Awakn will deliver evidence backed psychedelic therapies for Addiction in clinics in the UK and Europe and through licensing partnerships globally. 

Notable Highlights include: 

  • Strategic focus on better treating Addiction with psychedelics.
  • World leading team focused on psychedelic drug and therapy research. 
  • Strong drug and therapy development pipeline, specifically targeting Addiction.
  • Clinics, which will be the UK and EU’s leading medical psychedelic therapy delivery 
  • Closed $8.3M June 8
  • BRAND NEW LISTING … commencing trading on NEO

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson. 

Tags: , , , , , , , , , ,
Posted in Awakn Life Sciences Corp., Featured | Comments Off on VIDEO – Awakn Life Sciences Corp. $AWKN Is Addressing The Multi-Billion Dollar #Addiction Treatment Industry With #Psychedelics

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 9:06 AM on Saturday, June 19th, 2021

A weekly summary of Novamind news and media, including the announcement of a US$1,000,000 strategic investment in a Stealth Mode Drug Development Company. 

Novamind to Present at the H.C. Wainwright Psychedelics Conference on June 17, 2021

“Novamind has over five years of operational expertise with psychedelic medicine, a track record of innovative treatment protocol development, and strong clinical research partnerships with blue-chip pharmaceutical companies,” said CEO Yaron Conforti. “I’m excited to share our vision for the next chapter of mental health treatment at the Conference.”

June 15, 2021

Novamind Announces US$1,000,000 Strategic Investment in Stealth Mode Drug Development Company

The Strategic Investment leverages Novamind’s expertise in patient recruitment and patient management for the Investee’s development of novel treatments for neuropsychiatric disorders.

June 17, 2021

View all press releases

‘People are desperate to heal’: The push for psychedelic-assisted therapy in Canada

Global News paints a compelling picture about the need for psychedelic-assisted therapy in Canada. “I just had so many different experiences, where all my questions that I had written out, everything was answered for me.” says Laurie Brooks, who was diagnosed with colon cancer at age 54. “I’m able now to deal with the emotions as they come, and to sit with them and hold them.” 

The 10 Most Important Health Breakthroughs You Missed During the Pandemic

It’s been a year of progress as many health breakthroughs happened while the public’s attention was rightfully focused on a Covid vaccine. Time covers some significant steps forward, including a malaria vaccine that could help save some 400,000 lives a year and the promising results of MDMA and psilocybin studies. It’s important to note the therapy aspect of the psychedelic studies. Both MDMA and psilocybin were given to participants in conjunction with therapy. Yes, these drugs are powerful and help provide the right mindset for improving mental health, but it’s the therapy that really creates lasting change. And it’s why that’s such a big part of what we do at Novamind. 

Atai Life Sciences Announces Pricing of Upsized Initial Public Offering

Congratulations to Atai Life on listing to the Nasdaq. As an early strategic investor, we look forward to seeing Atai continue to deliver on its mission of “pioneering the development of highly effective mental health treatments.” Christian Angermayer

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – POET Technologies $PTK.ca $POETF Describes OFC Conference as an “Inflection Point”

Posted by AGORACOM-JC at 4:47 PM on Monday, June 14th, 2021

POET Technologies (PTK: TSXV) (POETF: OTCQX) Vivek Rajgarhia, Thomas Mika and I discuss the success of their demos at the  2021 Optical Fiber Communication Conference and Exhibition (OFC) .

POET hosted a Gold-level sponsored booth showcasing the company’s latest news, products and video demonstrations.

Vivek describes the conference as an “inflection point” … and the smiles on their faces are hard to ignore! 

Sit back and watch this powerful interview!

Tags: , , , , , ,
Posted in AGORACOM Via Satellite, POET Technologies | Comments Off on VIDEO – POET Technologies $PTK.ca $POETF Describes OFC Conference as an “Inflection Point”

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:54 AM on Saturday, June 12th, 2021

A weekly summary of Novamind news and media, including the announcement of a new psychedelic therapy protocol for frontline healthcare workers.

FEATURES  June 7, 2021

A Quarter of Growth

Green Market Report covers our fiscal Q3 earnings in their Psychedellux recap of the top business stories in the psychedelic medicine industry.

Novamind reported total revenue of $1.8 million, a 43% quarter-over-quarter, driven by increased patient volume at the Company’s four operating clinics.

View all media

Novamind Launches Psychedelic Therapy Protocol for Frontline Healthcare Workers

“Together with the Wholeness Center, we’re joining forces to offer a new therapy that will positively impact the people who show up every day and continue to provide critical healthcare for the public during—and after—this difficult time,” said Dr. Robison.

Click here to learn more about the Frontline KAP protocol

June 10, 2021

View all press releases

The Brain-Changing Magic of New Experiences

From GQ’s series on mental health comes a piece about the psychological reasons how new experiences can change how we perceive time and make us more resilient. It’s an interesting read and the author even compares trees blooming in spring to psychedelics. “Even the most mundane new experiences left me feeling genuinely elated.” There’s a reason for it too. From Dr. Laurie Santos, “Novel stimuli tend to activate regions of our brain that are associated with rewards.” At our Cedar Psychiatry clinics, we practice a holistic approach to mental health. Taking into account psychological, biological, social, environmental, and cultural influences. Learn more here.

Atai Life Sciences Announces Launch of Initial Public Offering

We’ve always believed in Atai’s vision to transform the treatment of mental health disorders. It’s why we became early strategic investment partners. Congratulations to Atai Life Sciences on launching their initial public offering. 

Follow @novamind_inc on Instagram

 
 

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – HPQ Silicon $HPQ.ca $HPQFF Hits Another Silicon Production Milestone As Pilot Plant Starts In Q4, Moving Company Closer To Awaiting Battery and Automobile Manufacturers $ENPH $NNO

Posted by AGORACOM-JC at 5:10 PM on Thursday, June 10th, 2021

HPQ Silicon Resources $HPQ $HPQFF is a Quebec-based company that is developing a portfolio of high value-added silicon products sought after by battery and electric vehicle manufacturers.

If that sounds a lot like what other small companies are saying lately, $HPQ differentiates itself as a leader of the pack thanks to the following:

Today, the Company announced a major milestone with this press release HPQ Silicon GEN3 PUREVAP™ Quartz Reduction Reactor Pilot Plant to be Commissioned in Q4 2021

To discuss the importance and the implications of this milestone, this excerpt from the press release says it all:

” Demand for higher purity Silicon, materials that the PUREVAP QRR was designed to produce – but one that traditional silicon producers have a difficult time making, is about to enter a massive growth phase, driven by worldwide demand from the silicones, solar, and batteries industries. The Covid-19 pandemic accelerated the closing of old inefficient traditional Silicon plants and combining this with the chronic under investment in new conventional Silicon plants that occurred in the past decade, and the need for more efficient and environmentally friendly processes has created a perfect storm for the industry. HPQ should be a key beneficiary of this new reality.”

Watch this great interview with $HPQ CEO Bernard Tourillon to get the full picture on next steps!

Posted in AGORACOM Via Satellite, HPQ-Silicon Resources Inc. | Comments Off on VIDEO – HPQ Silicon $HPQ.ca $HPQFF Hits Another Silicon Production Milestone As Pilot Plant Starts In Q4, Moving Company Closer To Awaiting Battery and Automobile Manufacturers $ENPH $NNO

VIDEO – Liquid Avatar $LQID Digital ID and Monetization Gets Huge Boost From Joining Linux Global Public Health Project $MOS.ca $MOGO.ca $CTZ.ca

Posted by AGORACOM-JC at 9:49 AM on Thursday, June 10th, 2021

When the Facebook data privacy scandal broke out, the world woke up to just how badly our individual data was being traded, used and most importantly, the amount of profit being generated by major corporations at our expense.

This led to the enactment of the biggest data privacy laws in history.  Specifically, General Data Protection Regulation (GDPR) out of Europe and the California Consumer Privacy Act (CCPA).

Enter $LQID. The Company Turns The Problem Of Data Privacy Into A Profit For Individuals, While Providing Big Businesses With New & Compliant Business Models.

More than just lip service, $LQID has made some major announcements, including joining the Trust Over IP Foundation, which includes over 170 members including IBM, Mastercard, Accenture and many other global leaders who are defining a complete architecture for Internet-scale digital trust.

Does that sound like a mouthful?  Yeah, it does.  But all you have to really understand for now is that digital ID, privacy and monetization is going to become a reality in the very near future.  Government regulations are enforcing it.  Consumers are demanding it and $LQID is delivering it at such an advanced scale that the Trust Over IP Foundation provided them with a strategic role as a Steering Member.

If that wasn’t enough proof for you, Google  validated the $LQID business model with this stunning announcement at the beginning of March: 

 Google announces major shift away from precision-targeting of ads based on everything you do on the internet

  • Google believes these types of tracking methods don’t “meet rising consumer expectations for privacy, nor will they stand up to rapidly evolving regulatory restrictions, and therefore aren’t a sustainable long term investment.”
  • Google is experimenting with tools in its Privacy Sandbox that are designed to allow advertising to continue to work on the web but in a less privacy-encroaching way.
  • “Keeping the internet open and accessible for everyone requires all of us to do more to protect privacy — and that means an end to not only third-party cookies, but also any technology used for tracking individual people as they browse the web,” David Temkin, Google’s director of product management for ads privacy and trust,

 What is the potential outcome of this major shift by Google?

  “Google’s decision could upend the ad industry, which has relied on these types of tracking tools”  

Now the data privacy and monetization game is underway with LQID sitting in a great position within the industry and the dominant position within the small cap world.  

That dominant position got even stronger when $LQID announced Liquid Avatar Congratulates the Ontario Government on the Release of its Digital Strategy  

WHY IS THIS SO IMPORTANT?

If consumers are going to switch to Liquid Avatar to protect and monetize their identity, the switch to Digital ID by Canada’s biggest Province is simply a monster catalyst:  The Ontario government strategy outlines ways in which it plans to harness the potential of the digital economy and better utilize data. Included in the plan are tangible commitments such as: 

  • the creation of a new data authority; 
  • a new digital artificial intelligence (AI) framework to guide responsible use of AI; and 
  • the introduction of a new government-issued digital ID that lets people prove who they are online.

Today, $LQID’s dominant position grew even stronger with the announcement Liquid Avatar Joins Linux Foundation Public Health Cardea Project. Why is this initiative so important?

Cardea is a complete ecosystem that can be used by public health authorities, governments, organizations, and industries to enable people to maintain their privacy while holding and using an easily verifiable, trustworthy, unalterable proof of a health test or vaccination.

One of the first projects to provide the related technology and guidance for implementation of the recently announced Global COVID Certificate Network (GCCN), also from Linux Foundation Public Health, Cardea helps facilitate the safe and free movement of individuals globally during the COVID pandemic.

Watch this interview with CEO David Lucatch for an even deeper discussion into what this all means for $LQID and YOU.

Tags: , , , , , , ,
Posted in AGORACOM Via Satellite, All Recent Posts, Liquid Avatar | Comments Off on VIDEO – Liquid Avatar $LQID Digital ID and Monetization Gets Huge Boost From Joining Linux Global Public Health Project $MOS.ca $MOGO.ca $CTZ.ca

The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 10:23 AM on Saturday, June 5th, 2021

A weekly summary of Novamind news and media, including a report of our fiscal Q3 financial results and operating highlights.

FEATURES  June 4, 2021

Psychedelic Healing,Here and Now

At Novamind, we’re preparing for the future of psychedelic medicine, but we’re also treating people today and the results have been life changing.

“This is the first treatment that’s ever given me any relief from suicidal ideations. It’s like they’re gone.”

FEATURES  June 1, 2021

More Than Just a Treatment for Depression

Novamind CMO Reid Robison speaks to the Toronto Sun about why ketamine is a game changer for treating eating disorders.

“I was sitting with people before, during and after treatment and I was blown away by what I saw. It’s not just a treatment for depression.”

FEATURES June 2, 2021

Growing at Scale

Behavioral Healthcare Executive covers our fiscal Q3 earnings report, detailing growth and forecasted clinic visits.

“Novamind, a mental health company that specializes in psychedelic medicine, this week announced revenues of $1.85 million for its fiscal quarter ending March 31, a 43% increase over the prior quarter. With its previously announced plans to open 4 new clinics, doubling the size of its network, between July and September, Novamind said in its earnings report that it expects to increase patient volume to more than 65,000 clinic visits in 2021, which would represent a 225% increase year-over-year.”

View all media

Novamind Reports Fiscal Q3 Financial Results and Operating Highlights

“Since listing on the CSE this January, Novamind has demonstrated its ability to rapidly scale access to innovative mental health treatment and psychedelic medicine,” said Yaron Conforti, CEO and Director, Novamind. “The contract with Merck to research a promising new drug, leveraged our expertise in patient recruitment and patient management. Novamind will continue to execute on its aggressive growth initiatives in 2021, further expanding organically and through acquisitions ahead of the FDA’s anticipated approvals of MDMA and psilocybin.” 

June 1, 2021

View all press releases

Researchers to Hone In On Most Therapeutic Doses of LSD

Identifying the correct dose for therapeutic settings is a crucial step in the path towards optimizing the healing power of psychedelics. In this article, Psychedelic Spotlight details new research studying the optimal LSD dosage for the treatment of mental health disorders. We look forward to more research and clinical trials in the future and will prepare for the time when LSD can be used as a treatment option in our clinics. 

The psychologists signing up for psychedelic therapy training: ‘Amazing things can happen’

The promise of psychedelic medicine is too great to ignore for Campbell Townsend, an Australian-based psychologist who is training in psychedelic-assisted psychotherapy. The Australian government has recently committed $15m to psychedelic clinical trials and support is growing in that country. There is significant momentum growing. Staying at the forefront of psychedelic research, Novamind is currently developing protocols for ketamine-assisted psychotherapy that will standardize and provide best-practice treatment methods for the widespread use of psychedelic medicine.

Follow @novamind_inc on Instagram

For further information, contact:

Bill Mitoulas
Investor Relations
Telephone: +1 (416) 479 9547
Email: [email protected]

Tags: , , , , , ,
Posted in All Recent Posts, Novamind Inc. | Comments Off on The Roundup – @Novamind_Inc $NM.ca $NVMDF $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

Posted by AGORACOM-JC at 5:57 PM on Thursday, June 3rd, 2021

As if today’s press release wasn’t good enough Empower Clinics Announces Major Expansion with Proposed Acquisition of Medisure Canada. Diabetes Tests and Devices Carried In 4,000 Pharmacies and Generated $1.9m in 2020 Revenue, shareholders also received this injection of confidence from CEO

Steve McAuley:

“As I’ve stated to our shareholders on multiple occasions throughout 2021, Empower is in the strongest position it has ever been and will continue to grow every aspect of our business unabated and without interruption. In addition to this acquisition, in the last 30 days alone we have announced expansions of our clinics, gone live on our KAI Saliva RT-PCR test with Air Canada and are very advanced on tripling the size of the KAI Medical Laboratory facility. We are hitting on all cylinders and well on our way to becoming a major vertically integrated healthcare company. I fully expect Empower to have continued strong business announcements in June and throughout 2021″

If that was all, it would be a great day … and it was with $CBDT closing up 16.5% on 7.5M shares to $0.53 … but then Steve shared some powerful information about leveraging this acquisition with large US pharmacies.  

Who did he name? 

Watch this great interview with CEO Steve McAuley.

Tags: , , , , , , , ,
Posted in AGORACOM Via Satellite, Empower Clinics Inc. | Comments Off on VIDEO – Empower Clinics $CBDT.ca $EPWCF In Advanced Discussions With Large US Pharmacies As Proposed Acquisition Includes Products In 4,000 Canadian Pharmacies $LMD.ca $DOC.ca $DOCRF $WELL.ca $PRN.ca

VIDEO – Draganfly $DFLY Hits Record Revenue And NASDAQ Is In Sight. CEO Cam Chell Says “DraganFly Will Become The #1 or #2 Drone Technology Company In The World $FLT.ca $UAVS $ALPP

Posted by AGORACOM-JC at 5:35 PM on Thursday, June 3rd, 2021

Most of us know drones for their recreational uses or perhaps even as simple commercial applications for things like real estate videos.

But the fact of the matter is that drone usage is about to go parabolic with huge corporations adopting them for a wide-use of applications that most never dreamed of such as:

  • To provide Internet connections in remote locations. 
  • To collect crowd data.

In short, the drone industry is booming in ways people can’t imagine because the industry is shifting from the drones themselves (hardware) to drone technology and solutions (software)… and the one company that is delivering the most challenging applications is DraganFly (DFLY: CSE) (DFLYF:OTCQB) (3U8:FSE)

DraganFly is an award-winning drone manufacturer and technology developer that is actually delivering some pretty incredible achievements, milestones and even history:

  • Established in 1998 DFLY is considered the oldest commercial drone company in the world
  • Built the first drone that saved a life
  • Boasts the first drone to be inducted into the Smithsonian National Air & Space Museum
  • Developing a Vaccine Drone Delivery Payload System (it’s way more complicated than just transporting vaccines)
  • Detect infectious conditions in a person from a distance of 190 feet
  • Conduct phenotyping, data collection and analysis by the USDA

Clients include:

  • Ford
  • Warner Brothers
  • Suncor Energy
  • Shell
  • Redbull
  • Government of Canada 
  • Ontario Provincial Police, 
  • Australian Federal Police, 
  • Royal Canadian Mounted Police, 
  • Illinois State Police,
  • Shell
  • Dow 

If you want ultra-cool consider that DFLY’s Vital Intelligence technology was selected for implementation by Knightscope, a leader in a leader in autonomous robot security capabilities.  

All of this has translated into financial success with 2020 Revenue hitting $4.36M up 216% … and now a record Q1 with $1.53M up 210%.

With all of this under the Company’s belt, it’s easy to see why CEO Chell believes DFLY will become one of the top 2 drone companies in the world and why they near the end of the process of listing on NASDAQ.

If you believe in the massive parabolic growth in the use of drones for almost everything we do in this world, or want to learn, then watch / listen to this powerful interview with Draganfly CEO and Chairman, Cameron Chell.

Tags: , , , , , , , ,
Posted in AGORACOM Via Satellite, Draganfly Inc. | Comments Off on VIDEO – Draganfly $DFLY Hits Record Revenue And NASDAQ Is In Sight. CEO Cam Chell Says “DraganFly Will Become The #1 or #2 Drone Technology Company In The World $FLT.ca $UAVS $ALPP

« Older Entries
Newer Entries »